Loading...
ESMO congress Solid Tumors 20222025-01-28T17:00:13+01:00

ESMO 2022 Solid Tumors – hybrid, Paris

 

Lecture Board: Myriam Chalabi, MD, PhD; Omid Hamid, MD; Jamie R. Merchan, MD; Armando Orlandi, MD, PhD; Matthias Pinter, MD, PhD
Medical Writer: Florence Boulmé, PhD; Eva Eckelhart, PhD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ESMO 2022  – Solid Tumors

ESMO 2020 Solid Tumors English Slide Kit

Slide Kit NSCLC, gastric cancer and other solid tumors

ESMO 2020 Solid Tumors English

Full report (english)

EXPERT VIDEOS

All video interviews from ESMO Solid Tumors 2022

Stacey A. Cohen explains if ctDNA can detect MRD and predict recurrence in patients with colon cancer in a real-world setting, if it should be used in daily clinical practice or as a surveillance biomarker in stage II ctDNA-negative colon cancer patients. Moreover, she depicts how the treatment of patients with colon cancer might change in the foreseeable future.

Go to Top